{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BioLineRx Ltd."},"Symbol":{"label":"Symbol","value":"BLRX"},"Address":{"label":"Address","value":"2 HAMA'AYAN STREET, MODI'IN, 7177871, Israel"},"Phone":{"label":"Phone","value":"+972 86429100"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions."},"CompanyUrl":{"label":"Company Url","value":"https://www.biolinerx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Irit Gliko-Kabir","title":"Vice President-Clinical Operations"},{"name":"Philip Adam Serlin","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}